Healthcare / BiotechnologyKOSDAQ
$36050.00
-1900.00 (-5.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-8.4B · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$391.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.8%
↓Gross Margin
52.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+85.1%
FCF CAGR
—
FCF margin
-324.7%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.95B · net income $-9.01B · FCF $-9.58B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.95B | $2.95B | $2.30B | $578.1M | $465.6M |
| Net Income | $-9.01B | $-9.01B | $-5.73B | $-22.79B | $-11.37B |
| EBITDA | $-7.63B | $-7.63B | $-1.63B | $-19.23B | $-8.62B |
| EPS | -906.00 | -906.00 | -1035.00 | -5378.00 | -13418.00 |
| Gross Margin | 52.2% | 52.2% | 63.6% | 87.0% | 100.0% |
| Operating Margin | -385.2% | -385.2% | -396.5% | -1255.1% | -1155.3% |
| Net Margin | -305.4% | -305.4% | -249.2% | -3941.3% | -2442.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.06 | -0.00 | -0.01 |
| Cash Flow | |||||
| Free Cash Flow | $-9.58B | $-9.58B | $-8.40B | $-5.98B | $-4.64B |
| Returns | |||||
| ROE | -31.8% | -31.8% | -36.4% | 43.4% | 37.4% |
| Valuation | |||||
| P/B | 12.64 | 12.64 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 28.3% | 28.3% | 298.0% | 24.2% | — |
| EPS Growth | 12.5% | 12.5% | 80.8% | 59.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+105.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1035.00 → -906.00
Residual
+105.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.